Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €33.98 EUR
Change Today +1.89 / 5.89%
Volume 600.0
MYD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:32 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYD) Snapshot

Open
€32.59
Previous Close
€32.09
Day High
€33.98
Day Low
€32.20
52 Week High
03/20/15 - €35.08
52 Week Low
11/24/14 - €25.26
Market Cap
2.3B
Average Volume 10 Days
200.3
EPS TTM
--
Shares Outstanding
68.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYRIAD GENETICS INC (MYD)

myriad genetics inc (MYD) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYD) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The company’s molecular diagnostic tests are designed to analyze genes expression levels, and proteins to assess an individual’s risk for developing disease later in life; diagnose diseases and determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, including myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; BRACAnalysis and BART, sequencing tests for hereditary breast and ovarian cancer; BRACAnalysis CDx sequencing test for use as a companion diagnostic in identifying ovarian cancer patients with deleterious suspected deleterious germline; and Tumor BRACAnalysis CDx sequencing test used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS sequencing test for colorectal and uterine cancer; COLARIS AP sequencing test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, an RNA expression test for prostate cancer; EndoPredict expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; and myPlan lung cancer, an RNA expression test for lung cancer. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

2,038 Employees
Last Reported Date: 08/12/15
Founded in 1991

myriad genetics inc (MYD) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $568.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $734.0K
Chief Scientific Officer
Total Annual Compensation: $733.6K
Consultant
Total Annual Compensation: $997.0K
Compensation as of Fiscal Year 2014.

myriad genetics inc (MYD) Key Developments

Myriad Genetics, Inc. Receives Favorable Medicare Final Coverage Decision for the Prolaris(R) Test

Myriad Genetics Inc. announced that Noridian has issued a final local coverage determination (LCD) for Prolaris®, Myriad's pioneering prognostic test for assessing the aggressiveness of prostate cancer. This decision follows a final LCD decision from Palmetto GBA on January 15, 2015. The final LCD is posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services website with an effective date of October 15, 2015 and provides Medicare coverage for prostate cancer patients defined as low and very low risk by the National Comprehensive Cancer Network (NCCN). The Medicare coverage decision extends reimbursement for testing to the approximately 60,000 patients diagnosed each year with localized prostate cancer in the United States who meet the criteria of a Gleason score =6 and serum prostate specific antigen (PSA) level <10 ng/ml.

Myriad Genetics Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015; Provides Earnings Guidance for the First Quarter of Fiscal 2016 and for the Fiscal Year 2016

Myriad Genetics Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended June 30, 2015. For the quarter, the company reported total revenues of $189.9 million against $188.8 million a year ago. Operating income was $36.2 million against $53.3 million a year ago. Adjusted operating income was $48.2 million against $56.3 million a year ago. Net income was $18.7 million or $0.26 per diluted share against $33.7 million or $0.43 per diluted share a year ago. Adjusted EPS was $0.41 against $0.48 a year ago. Income before income taxes was $35.5 million against $52.6 million a year ago. Non-GAAP operating income was $48.2 million against $56.3 million a year ago. Non-GAAP net income was $29.4 million or $0.41 per diluted share against $37.2 million or $0.48 per diluted share a year ago. Free cash flow $49.0 million against $36.3 million a year ago. For the year, the company reported total revenues of $723.1 million against $778.2 million a year ago. Operating income was $134.2 million against $274.4 million a year ago. Adjusted operating income was $167.3 million against $291.6 million a year ago. Net income was $80.2 million or $1.08 per diluted share against $176.2 million or $2.25 per diluted share a year ago. Adjusted EPS was $1.45 against $2.43 a year ago. Income before income taxes was $134.9 million against $277.8 million a year ago. Net cash provided by operating activities was $140.5 million against $190.2 million a year ago. Capital expenditure was $23.9 million against $14.3 million a year ago. Non-GAAP operating income was $167.3 million against $291.6 million a year ago. Non-GAAP net income was $108.0 million or $1.45 per diluted share against $189.6 million or $2.43 per diluted share a year ago. Free cash flow $116.6 million against $175.9 million a year ago. For the fiscal year 2016, the company expects revenue to be $750 million -$770 million. GAAP diluted net income per share is expected to be $1.45 to $1.50. Non-GAAP diluted net income per share is expected to be $1.60 to $1.65 For the fiscal first quarter 2016, the company expects revenue to be $176 million to $178 million. Adjusted EPS is expected to be $0.34 to $0.36. GAAP diluted EPS to be $0.30 to $0.32.

Myriad Genetics Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 10:00 AM

Myriad Genetics Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 10:00 AM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: Mark Christopher Capone, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €33.98 EUR +1.89

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $28.50 USD +0.16
Alliance HealthCare Services Inc $14.09 USD +0.18
Foundation Medicine Inc $23.65 USD +0.72
Genomic Health Inc $26.33 USD -0.02
RadNet Inc $6.13 USD +0.19
View Industry Companies
 

Industry Analysis

MYD

Industry Average

Valuation MYD Industry Range
Price/Earnings 34.0x
Price/Sales 3.5x
Price/Book 3.8x
Price/Cash Flow 31.4x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.